

See related Letters to the Editor, "Confounding of Race/Ethnicity and Age in the Survival among Veterans Obtaining Dialysis in VA and Non-VA Settings," on page 1337.

Virginia Wang<sup>1,2,3</sup>, Cynthia J. Coffman<sup>1,4</sup>, Ann M. O'Hare<sup>5,6</sup>, and Matthew L. Maciejewski<sup>1,2,3</sup>

<sup>1</sup>Health Services Research and Development, Durham Veterans Affairs Health Care System, Durham, North Carolina;

<sup>2</sup>Department of Population Health Sciences,

<sup>3</sup>Division of General Internal Medicine, Department of Medicine, and

<sup>4</sup>Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina;

<sup>5</sup>Center for Health Services Research in Older Adults, Puget Sound Health Care System, Seattle, Washington; and

<sup>6</sup>Department of Medicine, University of Washington, Seattle, Washington

JASN 30: 1337–1339, 2019.

doi: <https://doi.org/10.1681/ASN.2019040402>

## The Case for Selective Withdrawal of Antidepressants in Patients with Advanced Kidney Disease

We read with interest "Comparative cardiac safety of selective serotonin reuptake inhibitors among individuals receiving maintenance hemodialysis" by Assimon *et al.*<sup>1</sup> This large retrospective analysis found that patients on hemodialysis who initiated selective serotonin reuptake inhibitors (SSRIs) with higher QT-prolonging potential (citalopram and escitalopram) had a significantly increased risk of sudden cardiac death (adjusted hazard ratio, 1.18; 95% confidence interval, 1.05 to 1.31) compared with patients who initiated SSRIs with lower QT-prolonging potential (fluoxetine, fluvoxamine, paroxetine, and sertraline). Given the lack of evidence regarding the efficacy of SSRIs for major depressive disorder in patients with advanced kidney disease and the prevalence of premature cardiovascular mortality in this setting, the findings of Assimon *et al.*<sup>1</sup> raise important questions about the use of these agents in this context.

Depression is a common comorbidity among patients with advanced kidney disease,<sup>2</sup> although diagnosis is complicated by the overlap of clinical features of these two conditions. Notwithstanding this, depression in this setting is associated

with adverse clinical outcomes, including increased mortality risk.<sup>3</sup> It is far from clear, however, whether the association is independent of antidepressant use. Three randomized, placebo-controlled trials of SSRIs in individuals with kidney disease<sup>4–6</sup> have failed to provide evidence of benefit while signposting increased risks of adverse events (reviewed in ref. 7). A recent randomized trial comparing sertraline with cognitive behavioral therapy in patients on dialysis showed a modest difference in favor of sertraline,<sup>8</sup> although there was no control group.

We appreciate that additional randomized, controlled trials are needed in this area and that the study of Assimon *et al.*<sup>1</sup> is not able to provide evidence for the absolute mortality risk associated with antidepressant use. However, we feel that there is a real possibility that, in some patients at least, these agents may be doing more harm than good. Hence, it may be appropriate to consider whether withdrawing antidepressants in suitable patients may be the appropriate strategy. Withdrawal could mean withdrawing one agent and switching to another, withdrawing and switching to a psychological treatment, or stopping all together. Antidepressant withdrawal requires careful risk assessment, patient education and counseling, and a considered tapering regimen to mitigate symptoms of withdrawal.<sup>9</sup> We believe that there is a strong case for empirical studies of antidepressant withdrawal in suitable patients with advanced kidney disease.

### DISCLOSURES

None.

### REFERENCES

1. Assimon MM, Brookhart MA, Flythe JE: Comparative cardiac safety of selective serotonin reuptake inhibitors among individuals receiving maintenance hemodialysis. *J Am Soc Nephrol* 30: 611–623, 2019
2. Palmer S, Vecchio M, Craig JC, Tonelli M, Johnson DW, Nicolucci A, et al.: Prevalence of depression in chronic kidney disease: Systematic review and meta-analysis of observational studies. *Kidney Int* 84: 179–191, 2013
3. Chilcot J, Guirguis A, Friedli K, Almond M, Day C, Da Silva-Gane M, et al.: Depression symptoms in haemodialysis patients predict all-cause mortality but not kidney transplantation: A cause-specific outcome analysis. *Ann Behav Med* 52: 1–8, 2018
4. Blumenfeld M, Levy NB, Spinowitz B, Charytan C, Beasley CM Jr., Dubey AK, et al.: Fluoxetine in depressed patients on dialysis. *Int J Psychiatry Med* 27: 71–80, 1997
5. Friedli K, Guirguis A, Almond M, Day C, Chilcot J, Da Silva-Gane M, et al.: Sertraline versus placebo in patients with major depressive disorder undergoing hemodialysis: A randomized, controlled feasibility trial. *Clin J Am Soc Nephrol* 12: 280–286, 2017
6. Hedayati SS, Gregg LP, Carmody T, Jain N, Toups M, Rush AJ, et al.: Effect of sertraline on depressive symptoms in patients with chronic kidney disease without dialysis dependence: The CAST randomized clinical trial. *JAMA* 318: 1876–1890, 2017
7. Chilcot J, Hudson JL: Is successful treatment of depression in dialysis patients an achievable goal? *Semin Dial* 32: 210–214, 2018
8. Mehrotra R, Cukor D, Unruh M, Rue T, Heagerty P, Cohen SD, et al.: Comparative efficacy of therapies for treatment of depression for patients undergoing maintenance hemodialysis: A randomized clinical trial. *Ann Intern Med* 170: 369–379, 2019

Published online ahead of print. Publication date available at [www.jasn.org](http://www.jasn.org).

**Correspondence:** Dr. Joseph Chilcot, Institute of Psychiatry, Psychology & Neuroscience, King's College London, 5th Floor Bermondsey Wing, London Bridge, SE1 9RT, United Kingdom. Email: [joseph.chilcot@kcl.ac.uk](mailto:joseph.chilcot@kcl.ac.uk)

Copyright © 2019 by the American Society of Nephrology

9. Horowitz MA, Taylor D: Tapering of SSRI treatment to mitigate withdrawal symptoms [published online ahead of print March 5, 2019]. *Lancet Psychiatry* doi:10.1016/S2215-0366(19)30032-X

See related Letters to the Editor, "Authors' Reply," on page 1340.

### Joseph Chilcot<sup>1</sup> and Ken Farrington<sup>2,3</sup>

<sup>1</sup>Psychology Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom;

<sup>2</sup>Renal Unit, Lister Hospital, Stevenage, United Kingdom; and

<sup>3</sup>Postgraduate Medicine, The University of Hertfordshire, Hatfield, United Kingdom

JASN 30: 1339–1340, 2019.

doi: <https://doi.org/10.1681/ASN.2019030308>

## Authors' Reply

We thank Chilcot and Farrington<sup>1</sup> for their interest in our paper<sup>2</sup> and thoughtful comments surrounding the treatment of depression in hemodialysis patients. We agree with the letter writers that our observational study was not designed to evaluate the effect of antidepressant pharmacotherapy (versus no treatment) on mortality among individuals with hemodialysis-dependent ESRD. Under our active comparator new-user design, we could only conclude that the initiation of a higher (citalopram and escitalopram) versus lower (fluoxetine, fluvoxamine, paroxetine, and sertraline) QT-prolonging potential selective serotonin reuptake inhibitor (SSRI) was associated with a higher risk of sudden cardiac death.<sup>2</sup> Our study was designed to reflect a clinician's decision to prescribe an SSRI with higher versus lower QT-prolonging potential to a hemodialysis patient (*i.e.*, a treatment choice encountered in real-world practice).<sup>2–4</sup> The study provides population-specific safety information that clinicians can consider when prescribing SSRI therapy to hemodialysis patients.

## ACKNOWLEDGMENTS

Dr. Assimon and Dr. Flythe are supported by grant R03 HS026801 from the Agency for Healthcare Research and Quality. Dr. Flythe is supported by grant K23 DK109401 from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.

## DISCLOSURES

Dr. Assimon and Dr. Flythe have received investigator-initiated research funding from the Renal Research Institute, a subsidiary of Fresenius Medical Care, North America. In the last 2 years, Dr. Flythe has received speaking honoraria from American Renal Associates; the American Society of Nephrology; Dialysis Clinic, Inc.; the National Kidney Foundation; and multiple universities. Dr. Flythe is on the medical advisory board of NxStage Medical, Inc. and has received consulting fees from Fresenius Medical Care, North America.

## REFERENCES

1. Chilcot J, Farrington K: The case for selective withdrawal of antidepressants in patients with advanced kidney disease. *J Am Soc Nephrol* 30: 1339, 2019
2. Assimon MM, Brookhart MA, Flythe JE: Comparative cardiac safety of selective serotonin reuptake inhibitors among individuals receiving maintenance hemodialysis. *J Am Soc Nephrol* 30: 611–623, 2019
3. Velentgas P, Dreyer NA, Nourjah P, Smith SR, Torchia MM, editors: *Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide*, Rockville, MD, Agency for Healthcare Research and Quality, 2013
4. Brookhart MA: Counterpoint: The treatment decision design. *Am J Epidemiol* 182: 840–845, 2015

See related Letters to the Editor, "The Case for Selective Withdrawal of Antidepressants in Patients with Advanced Kidney Disease," on pages 1339–1340.

### Magdalene M. Assimon<sup>1</sup> and Jennifer E. Flythe<sup>1,2</sup>

<sup>1</sup>University of North Carolina Kidney Center, Division of Nephrology and Hypertension, Department of Medicine, UNC School of Medicine, Chapel Hill, North Carolina; and

<sup>2</sup>Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, North Carolina

JASN 30: 1340, 2019.

doi: <https://doi.org/10.1681/ASN.2019040431>

Published online ahead of print. Publication date available at [www.jasn.org](http://www.jasn.org).

**Correspondence:** Dr. Magdalene M. Assimon, University of North Carolina Kidney Center, Division of Nephrology and Hypertension, Department of Medicine, University of North Carolina School of Medicine, 7024 Burnett-Womack CB #7155, Chapel Hill, NC 27599-7155. Email: [massimon@med.unc.edu](mailto:massimon@med.unc.edu)

Copyright © 2019 by the American Society of Nephrology